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Purpose: To determine trends in utilization and off-label use of polyethylene glycol (PEG) 
4000 in children and to determine the prevalence of constipation.
Methods: Retrospective cross-sectional analyses were conducted from 1997 to 2007 in a French 
health care database comprising general practitioners and pediatricians. Patients prescribed PEG 
4000 (Forlax®; Ipsen Pharma, Paris, France) were used to assess PEG 4000 use; constipation was 
defined by a diagnosis of constipation or use of any laxative. Analyses used linear r  egression 
models to fit trends over time.
Results: The study sample consisted of a nationally representative sample of 1200 general 
practitioners with 1.6 million patient medical records and 100 pediatricians with 70,000 patient 
medical records. Data were available from 1997 to 2007 for general practitioners and from 
2003 to 2007 for pediatricians and were extrapolated to the national level. Among both groups 
of physicians there were statistically significant increases in the number of patients pre-
scribed 4 g. For the 10 g dose, there was a decline among pediatricians. The largest increases 
were in children aged 0–8 years and in females. The prevalence of constipation in children aged 
0–18 years was 4%.
Conclusion: There has been an increase in the use of PEG 4000 laxative in children, particularly 
in the younger ages and in females. Use of the 4 g dose has increased. There was considerable 
off-label use of PEG 4000 in children aged 0–8 years before the introduction of the 4 g pediatric 
dose, which reflected clinical need.
Keywords: polyethylene glycol, macrogol 4000, children, drug utilization, database, laxative, 
off-label use, prevalence, constipation, time trends
Introduction
Constipation in children is a common condition.1 The prevalence of constipation varies 
from 1% to 30% depending on the diagnostic methodology employed, the sampling 
frames, and the populations sampled.2 The prevalence of constipation over time is 
uncertain3 and few population-based studies exist in the literature.
The lack of studies on constipation in children, despite its high prevalence, may 
be due to a view that constipation is something that children “grow out of.”   However, 
a long-term follow-up study of chronically constipated children found that in a 
third of their subjects, complaints of constipation persisted into young adulthood.4 
  Approximately 50% of the children also experienced at least one relapse within the first 
5 years after initial successful treatment.4 After intensive medical and/or psychosocial 
treatment, a subgroup of children with persistent constipation will have an unsuccessful 





physical and emotional distress and is associated with a 
significantly decreased quality of life, another factor arguing 
against the problem’s supposedly benign nature.6
More studies have been conducted on the population 
prevalence of constipation in adults, with report rates that 
range from 2% to 28%.7–14 A recent study of a questionnaire-
based assessment of constipation in nationally representative 
samples of subjects found France to have the highest 
prevalence of constipation (14.0%) among the other 
European countries in the study (the prevalence rates for 
Germany, Italy, and the UK were 5.4%, 8.0%, and 7.7%, 
respectively).15 For French subjects under age 30 years (no 
lower age limit was reported in the study), the prevalence 
was 12%.15
The use of laxatives is not well documented, although 
a few studies in the USA indicate that it is considerable 
in children, with a heavy medical cost burden that is 
increasing over time.3,16 In the USA, the use of laxatives 
is greater in children and is increasing.3 The increase in 
laxative use from 1997 to 2006 was predominantly among 
hyperosmolar laxatives.16 A multicountry cross-sectional 
survey documented laxative use but could not differentiate 
the types of laxatives used.14 Additionally, there is a suspicion 
that off-label use of PEGs was common due to the clinical 
need for laxatives in younger children until the approval of 
agents specifically for them.17
Few data are available in Europe on laxative use. 
However, in France, where constipation has a higher reported 
prevalence than in many other EU countries,15 a large 
health care database was available to obtain these data (see 
Methods). Therefore, the current study was conducted in 
children in France to:
•	 quantify the degree of use of hyperosmolar laxatives, such 
as polyethylene glycol (PEG) 4000 and to test whether 
PEG laxative use has increased over time
•	 describe and quantify time trends in use
•	 describe and quantify the degree of off-label use
•	 examine the influence of the introduction of a pediatric 
dose on prescription trends
•	 determine the prevalence of constipation in children in 
France.
Forlax® (Ipsen Pharma, Paris, France), a 4000 molecular 
weight macrogol PEG without electrolytes, is considered 
to be a frequently used PEG for constipation in France and 
was used to reflect patterns of hyperosmolar PEG laxative 
use in that country. It is packaged in two doses, 4 g and 10 g. 
In France, the 10 g dose was approved in 1995 for adults 
and children aged . 8 years. The 4 g dose was approved for 
children from age 6 months to 8 years and launched in July 
2005,3,16 thus allowing the quantification of the off-label use 
of Forlax to be feasible. Therefore, to track changes over time, 
the analysis used this particular trade-named product as a 
measure of PEG 4000 use for constipation in children.
Methods
This study was a retrospective cross-sectional observational 
study in the Longitudinal Patient Database (LPD), a database 
used by general practitioners and pediatricians in France over 
the period 1997 to 2007, held by the market research company 
Cegedim Strategic Data, France. The general practitioners 
and office-based pediatricians forming the panel of physicians 
for the study used clinical management software in their daily 
practice. The office-based active general practitioners and 
pediatricians uploaded anonymous and coded excerpts from 
the medical files of patients who had consulted them. The 
representativeness of the panel of physicians reflected France 
based on age, gender, and geography. Data items included: 
age, gender, medical history (event dates, diagnoses, risk 
factors, referrals to specialists), therapeutic history (date/
length of prescription, molecule/product, dose), additional 
information (test results, immunizations, height, weight, 
blood pressure), and date of data input.
For assessing hyperosmolar PEG laxative use, this 
study used patients prescribed the PEG 4000 product trade-
named Forlax as a measure of hyperosmolar PEG laxative 
use in France from 1997 to 2007. Inclusion criteria for 
the study included a prescription of Forlax at doses of 4 g 
and 10 g in subjects aged 0–18 years, at least once in each 
relevant year, from January 1, 1997 to December 31, 2007. 
Inclusion criteria for identifying constipation was one or 
more prescriptions of any laxative or enema (Code A06A 
of the Anatomical Therapeutic Classification [ATC]) or an 
assignment of a diagnosis of constipation in subjects aged 
0–18 years between January 1, 1997 and December 31, 
2007. As the data have already been collected and are totally 
anonymous, no ethical approval was required in France to 
conduct the analysis.
Statistical analysis used descriptive measures of binary 
data with total numbers and frequencies. The base population 
for the calculation of drug utilization in each year comprised 
patients aged 0–18 years prescribed Forlax 4 g and 10 g by 
general practitioners and pediatricians. The base population 
for the calculation of prevalence in 2007 comprised patients 
aged 0–18 years who had consulted general practitioners 
and/or pediatricians. Analyses used gender and the age groups 
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to examine for statistically significant increases with time in 
utilization and to quantify the trends. Time trends in patients 
prescribed PEG 4000 were analyzed by linear regression 
techniques following the ordinary least squares technique after 
the transformation of data, if required. Where a linear model 
was clearly inappropriate from inspection of the graphical plot 
of the data, an exponential model with transformation of the 
data using a logarithmic function was employed. Regression 
values are displayed using the beta coefficient, the standard 
error, the proportion of the variability of the data fitted by 
the model (R2) and statistical significance with P values. The 
Stata statistical package (Stata IC v 11; Stata Corp, College 
Station, TX) was used to conduct the analysis.
Results
The study sample consisted of 1200 general practitioners from 
a total of approximately 56,000 with 12.8 million children 
nationally who consulted them at least once in the relevant year, 
and 100 pediatricians from a total of approximately 2670. Data 
were available from 1997 to 2007 for general practitioners and 
from 2003 to 2007 for pediatricians. The general practitioners 
were representative of French general practitioners according 
to the criteria of age, gender, and geographical region (Table 1). 
The results from the sample in the study were extrapolated 
to the national level for France based on the number of 
subjects in the study population and are presented nationally.
Among general practitioners, there was an absolute 
increase in patients aged 0–18 years prescribed both doses 
of PEG 4000 during the period 1997 to 2007, with 15,002 
patients in 1997 and 133,952 patients in 2007 (test of trend 
Table 1 Comparison of general practitioners in the study sample 
and nationally in France
Variable Study sample France nationally
Age of physician
 , 41 9.8% 9.6%
  41–45 14.2% 14.3%
  46–50 22.7% 22.3%
  51+ 53.4% 53.9%
Gender
  Male 78.3% 74.7%
  Female 21.8% 25.3%
region of France
  West 18.1% 18.0%
  Paris region 19.6% 16.2%
  south West 15.0% 15.4%
  Central East 13.3% 13.9%
  south West 9.5% 10.9%
  north 9.3% 9.7%
  East 8.3% 8.8%
  Central West 6.9% 7.2%
P , 0.001; see Table 2 and Figure 1). The increase was gradual 
in older children aged 9–18 years: from 14,015 patients in 
1997 to 2005 to an abrupt increase to 60,194 patients in 
2007 (test of trend P , 0.001) (Figure 1). The increase was 
initially less steep in younger children aged 0–8 years, with 
987 patients in 1997 and 10,557 patients in 2004, followed 
by an abrupt increase to 32,799 patients in 2005 and rising to 
73,759 patients in 2007 (test of trend P , 0.001, Figure 1). 
The relative proportion of patients prescribed PEG 4000 in the 
9–18 years age group declined from 93.4% in 1997 to 44.9% 
in 2007, while the proportion of patients in the 0–8 year age 
group increased from 6.6% in 1997 to 55.1% in 2007.
A statistically significant trend (P , 0.001) described the 
pattern of increase in patients prescribed the 10 g dose, which 
rose from 15,002 in 1997 to 47,053 in 2007 (Figure 2). The 
4 g dose recorded 0 patients from 1997 to 2004, with a subse-
quent increase reaching 88,454 in 2007 (Figure 2). However, 
the trend was not statistically significant with either a simple 
linear or exponential model (Figure 2). The proportion of 
female patients prescribed the 10 g dose was greater than the 
proportion of males (increment per year of 1839 female patients 
prescribed compared with 1129 males, both statistically sig-
nificant) and for the 4 g dose the linear increment per year was 
18,409 females compared with 14,839 males, both statistically 
significant. The proportion of female patients prescribed the 
10 g dose declined from 70.4% in 1997 to 62.9% in 2007. 
The proportion of female patients prescribed the 4 g dose was 
fairly static at approximately 57% between 2005 and 2007.
Among pediatricians, there was an absolute increase in 
the number of patients prescribed both doses of PEG 4000 
from 2003 to 2007 in all children (aged 0–18 years), with 
20,734 patients in 2003 and 58,691 in 2007 (test of trend 
P = 0.01) (Table 3, Figure 3). There was a small increase 
among children aged 9–18 years over the 4 years available for 
the study, with 2818 patients in 2003 and 5242 in 2007 (test of 
trend P = 0.05, Figure 3). The number of patients prescribed 
PEG 4000 was greater in the younger (0–8 years) age group, 
with 17,916 patients in 2003, which increased after 2005 to 
53,449 patients in 2007 (test of trend P = 0.001) (Figure 3). 
The relative proportion of patients prescribed PEG 4000 in 
the 9–18 years age group declined from 13.6% in 2003 to 
8.9% in 2007, while the proportion in the 0–8 years age group 
increased from 86.4% in 2003 to 91.1% in 2007.
There was a decrease in the number of patients prescribed 
the 10 g dose, from 20,734 in 2003 to 8030 in 2007 (test of 
trend P = 0.03) (Figure 4). The number of patients prescribed 
the 4 g dose was recorded as 0 from 2003 to 2004 (as this 





in 2007 (Table 2). This trend was statistically significant 
(P = 0.03) (Figure 4) and applied to females and males.
Among general practitioners in the database, out of 
274,000 children who consulted in 2007, 10,309 had a 
diagnosis of constipation. Therefore, the prevalence of 
constipation in children aged 0–18 years treated at least once 
with any laxative or enema (A06A ATC codes), or identi-
fied by a diagnosis of constipation in 2007 was 3.8% among 
  general practitioners. Among   pediatricians in the database, 
















































Figure 1 number of patients prescribed PEG 4000 (Forlax®; ipsen Pharma, Paris, France) in children aged 0–8, 9–18, and 0–18 years, by calendar year among general practitioners.
Notes: smooth lines are the modeled data. Model (exponential) for patients aged 0–18 years: y = 9,895.2 e0.22x; (r2 = 0.93); P , 0.001. Model (exponential) for patients 
aged 0–8 years: y = 647.0 e0.41x; (r2 = 0.92); P , 0.001. Model (linear) for patients from 9 to 18 years old: y = 4,698.3x + 2,845.5; (r2 = 0.88); P , 0.001.
Abbreviations: n, number; PEG, polyethylene glycol.
Table 2 number of patients prescribed PEG 4000 (Forlax®; ipsen Pharma, Paris, France) among general practitioners by dose, gender, 
and year
Year All Forlax Forlax 10 g Forlax 4 g*












n % n % n % n % n % n %
1997 15,002  
(100%)
10,561 70.4 4441 29.6 15,002 10,561 70.4 4441 29.6 – – – – –
1998 19,482  
(100%)
13,618 69.9 5865 30.1 19,482 13,618 69.9 5865 30.1 – – – – –
1999 16,744  
(100%)
11,466 68.5 5278 31.5 16,744 11,466 68.5 5278 31.5 – – – – –
2000 24,381  
(100%)
17,879 73.3 6502 26.7 24,381 17,879 73.3 6502 26.7 – – – – –
2001 27,973  
(100%)
19,647 70.2 8326 29.8 27,973 19,647 70.2 8326 29.8 – – – – –
2002 29,481  
(100%)
19,674 66.7 9807 33.3 29,481 19,674 66.7 9807 33.3 – – – – –
2003 37,495  
(100%)
25,714 68.6 11,781 31.4 37,495 25,714 68.6 11,781 31.4 – – – – –
2004 45,074  
(100%)
28,331 62.9 16,743 37.1 45,074 28,331 62.9 16,743 37.1 – – – – –
2005 74,043  
(100%)
45,172 61.0 28,871 39.0 42,913 27,251 63.5 15,663 36.5 31,817 18,413 57.9 13,404 42.1
2006 128,348  
(100%)
75,077 58.5 53,270 41.5 44,651 28,919 64.8 15,731 35.2 84,780 46,770 55.2 38,010 44.8
2007 133,952  
(100%)
79,081 59.0 54,872 41.0 47,053 29,673 63.1 17,380 36.9 88,454 50,256 56.8 38,198 43.2
Notes: *Forlax 4 g launched in July 2005 in France; base for each year, patients aged 0–18 years treated at least once with Forlax 4 g and 10 g by general practitioners.




























































Figure 2 number of patients prescribed the 4 g, 10 g, and all doses of PEG 4000 (Forlax®; ipsen Pharma, Paris, France), by calendar year among general practitioners.
Notes: smooth lines are the modeled data. Model (exponential) for patients with prescriptions for all Forlax doses: y = 9,857.3 e0.22x; (r2 = 0.93); P , 0.001. Model (linear) for 
patients with prescription of Forlax 10 g: y = 3,485.6x + 10,550; (r2 = 0.96); P , 0.001. Model (linear) adjusted for patients with Forlax 4 g: y = 28,319x + 11,713; r2 = 0.80.
Abbreviations: n, number; PEG, polyethylene glycol.
Table 3 number of patients prescribed PEG 4000 (Forlax®; ipsen Pharma, Paris, France) among pediatricians by dose, gender, and year
Year All Forlax Forlax 10 g Forlax 4 g*











n % n % n % n % n % n %
2003 20,734  
(100%)
11,743 56.6 8991 43.4 20,734 11,743 56.6 8991 43.4 – – – – –
2004 21,981  
(100%)
11,465 52.2 10,516 47.8 21,981 11,465 52.2 10,516 47.8 – – – – –
2005 32,166  
(100%)
17,882 55.6 14,284 44.4 17,066 9461 55.4 7606 44.6 16,695 9164 54.9 7531 45.1
2006 54,298  
(100%)
28,285 52.1 26,013 47.9 9927 4874 49.1 5053 50.9 45,299 23,950 52.9 21,349 47.1
2007 58,691  
(100%)
32,179 54.8 26,513 45.2 8030 4060 50.6 3969 49.4 51,540 28,543 55.4 22,998 44.6
Notes: *Forlax 4 g launched in July 2005 in France; base: for each year, patients aged 0–18 years treated at least once with Forlax 4 g and 10 g among paediatricians.
Abbreviations: n, number; PEG, polyethylene glycol.
had a diagnosis of constipation. Therefore, the prevalence of 
constipation in children aged 0–18 years treated at least once 
with any laxative or enema (A06A ATC codes) or identified 
by a diagnosis of constipation in 2007 was 4.2% among 
pediatricians. The proportion of females conforming to this 
definition of constipation among general practitioners was 
57.1% and 53.2% among pediatricians.
Discussion
The is the first study to describe the temporal pattern of utiliza-
tion of hyperosmolar PEG laxatives, using patients prescribed 
Forlax as a representative agent for PEG use, in children aged 
0–18 years in France. The study demonstrates the large   overall 
increase in the use of PEG laxatives from 1997 to 2007. There 
have been consistent increases in patients prescribed PEG 
laxatives by general practitioners, with less dramatic and 
less consistent patterns observed among pediatricians. The 
changes have reflected much greater use in younger children 
aged 0–8 years by both general practitioners and pediatricians, 
and in females. However, for older children aged 9–18 years, 
general practitioners have prescribed an increasing number of 
patients PEG 4000, while the number of patients prescribed 
PEG 4000 by pediatricians has been almost static.
The statistical models have quantified the degree and pattern 
of changes in the use of hyperosmolar laxatives such as poly-
ethylene glycol (PEG) 4000 and demonstrate that the increases 
over time have been statistically significant. Regression models 





were able to fit the data extremely well in all analyses except 
one, and provide robust and statistically significant estimates 
for the increments each year between 1997 to 2007 in patients 
prescribed PEG 4000 in 4 g and 10 g doses, by gender, and 
by age. Information for Forlax 4 g was the exception as there 
were data for only three time points from 2005 to 2007, which 
limited the power of the statistical models.
The study is the first to show and quantify off-label use 
of PEG laxatives in France and describe its influence on 
prescription patterns. Children aged 0–8 years have been 
prescribed the PEG 4000 trade-named product since 1997 
by general practitioners and since 2003 by pediatricians (the 
earliest data available from the database). These prescriptions 
consisted of the 10 g dose as the 4 g dose was not launched 
in France until 2005. This represents off-label use, as the 
Summary of Product Characteristics for the 10 g dose states 
that it is for use in children older than 8 years.18 However, 
the study was unable to determine whether parents were 
requested to adjust the administration of the 10 g dose during 
the preparation of the medication. Nevertheless, the dramatic 
and rapid increase in the number of patients aged 0–8 years 
prescribed PEG 4000 laxatives, and in the 4 g dose among 
both general practitioners and pediatricians from the time 
the 4 g dose of Forlax was introduced (approved in 2005 for 
children from age 6 months to 8 years),19 revealed the large 
medical need for an approved laxative in this age group. The 
authors were not able to identify any studies that describe 
drug utilization of hyperosmolar laxatives in children in 
France with which to compare our results. However, prior 
to approval of the 4 g dose, there was a published clinical 
trial that used PEG 4000 as a comparator arm in young 
children,20 which may have influenced physicians to prescribe 
the 10 g dose of PEG 4000 as an off-label indication.
General practitioners have also been responsible for a 
large increase in the prescription of the 10 g dose, while 
pediatricians prescribed fewer patients the 10 g dose. This 
may reflect changing clinical practice, with pediatricians 
treating the more severe and younger cases, and general 
practitioners taking more responsibility for the less severe 
and older cases. The finding of a higher proportion of females 
prescribed PEG 4000 compared with males supports another 
study with nationally representative data from France in 
subjects ,30 years old.16 The present study found that 
increases in prescriptions of laxatives to females were greater 
than in males between 1997 and 2007.
The overall patterns of results in our study are supported 
by prescribing patterns over time observed in the USA using a 
different methodology. Data from a nationally representative 
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Figure 4 number of patients prescribed the 4 g, 10 g, and all doses of PEG 4000 
(Forlax®; ipsen Pharma, Paris, France), by calendar year by pediatricians.
Notes: smooth lines are the modeled data. Model (linear) adjusted for patients with 
a prescription of All Forlax doses: y = 10,823x + 5,104.5; r2 = 0.91; P = 0.011. Model 
(linear) adjusted for patients with a prescription of Forlax 10 g: y = 3,746.3x + 26,786; 
r2 = 0.88; P = 0.017.













































Figure 3 number of patients prescribed PEG 4000 (Forlax®; ipsen Pharma, Paris, France) in children aged 0–8, 9–18, and 0–18 years, by calendar year among pediatricians.
Notes: smooth lines are the modeled data. Model (linear) adjusted for the increase in the number of patients aged 0–18 years with a prescription of Forlax: y = 10,823x + 15,928; 
r2 = 0.91; P = 0.011. Model (linear) adjusted for the increase in the number of patients aged 0–8 years with a prescription of Forlax: y = 10,017x + 13,344; r2 = 0.92; P = 0.010. 
Model (linear) adjusted for the increase in the number of patients aged 9–18 years with a prescription of Forlax: y = 805.3x + 2,584.1; r2 = 0.77; P = 0.049.
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sample from the National Ambulatory Medical Care Survey, 
1997 to 2006, a similar time period to our study, observed 
an increase from 15% to 42% in the proportion of visits due 
to constipation (derived from ICD-9 codes or prescription 
of a laxative) where a (unspecified) hyperosmolar laxative 
was prescribed in children ,18 years old.3 Other age groups, 
including the 65+ age group, did not record such large 
increases in the proportion of visits due to constipation where 
a (unspecified) hyperosmolar laxative was prescribed.3 Thus, 
hyperosmolar laxatives were more likely to be prescribed 
to children than adults, reinforcing the importance of the 
findings of our study for public health. The higher use of PEG 
laxatives in children aged 0–8 years, after approval in 2005 
of the 4 g dose of Forlax for children from age 6 months to 
8 years, compared with children aged 9–18 years, is supported 
by the higher prevalence of constipation in younger children 
in the study by Liem et al.16 Although differences in meth-
odology, sampling frames, and populations sampled make 
direct comparisons between studies difficult, the trends over 
time observed within each study are more reliable.
Constipation in France among children aged 0–18 years 
is common and has a prevalence that is approximately 4%. 
This figure is a little higher than the prevalence of 1.1% found 
in a nationally representative sample of visits to physicians 
by US children aged 0–18 years, where the diagnosis was 
based on ICD-9 codes or laxative prescription records.16 The 
use of recorded ICD-9 codes may be the explanation for 
the lower prevalence figure in the US study compared with 
the present study. Reassuringly, the US sample also provided 
a figure of 51% for constipation in females,16 which is not 
very different to the 57% observed in this study. This study 
and the US study16 are at odds with prevalence estimates 
obtained from a cross-sectional survey of nationally repre-
sentative samples of subjects which found that the proportion 
of subjects under 30 years old reporting constipation (from 
a questionnaire) was 12% in France and 13% in the USA.15 
The use of a representative sample to detect constipation in 
patients who do not consult their physician for constipation 
and the looser criteria to define constipation than that used 
by physicians are likely explanations for the much higher 
prevalence rates of constipation in the study.15
There are several limitations to the present study, which 
used data collected routinely for clinical care. By using a single 
trade-named product (Forlax) as an indicator of PEG 4000 use, 
the utilization of  PEG 4000 laxatives in children may have been 
underestimated. Clinical opinion indicated that most children 
were given this product as the preferred PEG 4000 during the 
years of the study. However, this study did not have independent 
prescription or sales data to verify this assumption. Also, other 
PEGs such as PEG 4000 with electrolytes, and PEG 3350 with 
and without electrolytes would underestimate the degree of use 
of PEG laxatives for constipation in children, as represented 
by a single trade-named prescription product. Other non-PEG 
laxatives were also not included and will likewise be a source 
of underestimation of laxative use. Nonetheless, the absolute 
utilization rates and trends for the particular PEG 4000 in this 
study remain valid, though they may not describe the entire 
picture of laxative use for constipation in France. Patient 
medical records in the database refer to unique patients except 
when patients move between physician practices and may be 
double counted. Thus, although patients are able to change 
general practitioner and pediatrician, which could result in a 
loss of patients and some double counting, patient movement 
among children is low. Patient movement between physicians 
may pose problems for cohort analyses, but as this study used 
cross-sectional analyses based on the subjects in each practice 
in each year, this source of error would have been minimal 
and unlikely to affect trends over time. Since data are collected 
directly by the physicians and uploaded anonymously, it is not 
possible to refer back to patients’ files and perform site qual-
ity control and validation of the diagnosis of constipation. The 
comparable figure of 1.1% constipation (using ICD-codes and 
laxative prescriptions) in a nationally representative sample of 
visits to physicians in the USA indicates that the diagnosis for 
constipation in this study was appropriate. However, the quality 
of the information from daily clinical practice is assessed by 
administrative quality indicators. This and the fact that all data, 
which have already been collected without any influence from 
investigators (as may occur in protocol-driven observational 
studies of drug utilization), come from routine clinical practice 
also lends credibility to the data. The data from pediatricians 
and the 4 g dose may be subject to overfitting of the models as 
there were only 3 or 4 years of data available. However, given 
similar trends over a longer period of time from general prac-
titioners, the data from pediatricians are consistent and, hence, 
likely to be reasonably robust. Of course, the regression models 
are based on the data used and caution should be exercised in 
extrapolation of these models beyond the years studied or to 
other data sets. Nonetheless, they provide a comparison for 
future studies of laxative utilization.
Information on the indication for the prescription was 
not requested and it is assumed that most prescriptions were 
for constipation. Bowel cleansing may have accounted for 
a small number of prescriptions, more among pediatricians 
than among general practitioners, but this is likely to be an 
insignificant proportion and would have altered the results 
only marginally. Furthermore, it is not likely to have affected 
the observed trends over time, by age groups or gender.Clinical and Experimental Gastroenterology
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This study has found large absolute levels of utilization of PEG 
4000 laxatives and increasing use over time in younger and 
older children, among general practitioners and pediatricians 
in France. These findings may highlight an important public 
health issue to address for policy makers, clinicians, and 
parents. The results highlight the need for studies in other 
European countries to describe patterns and trends in utilization 
of different laxatives. Further research should be encouraged in 
this relatively neglected area to evaluate whether the prescribing 
is based on evidence-based guidelines,21 given that general 
practitioners are prescribing PEG laxatives for constipation 
more than previously, and whether outcomes have improved.
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